Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Total Non-current Liabilities
All obligations due after more than one year.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities turns positive
Q1 FY2026 total non-current liabilities was $0, compared with -$0 a year earlier.
Context
- Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (0) | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 total non-current liabilities of $0 is the 5th highest of the 6 companies compared; the peer median is $806K.
- Its year-over-year change of +100.0% is the 2nd highest of 6, against a peer median of +15.0%.
- Total non-current liabilities amounts to 0.0% of total assets for TELO, versus a peer median of 3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $279.76M | +15.0% | +0.0% | 212.9% | |
| Mar 2026 | $48.24M | -20.5% | -33.9% | 14.8% | |
| Mar 2026 | $806K | +301.0% | -66.3% | 3.1% | |
| Mar 2026 | $251K | +68.5% | -70.9% | 0.4% | |
| Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -37.3% | 0.0% | |
| Peer median (excluding TELO) | $806K | +15.0% | -37.3% | 3.1% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.